The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Blood Cancer J. 2021 Jul 1;11(7):124. doi: 10.1038/s41408-021-00515-2.

Authors

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
³ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Lin.Yi@mayo.edu.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Biological Products / adverse effects
Biological Products / therapeutic use*
Body Weight
Female
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, Large B-Cell, Diffuse / complications*
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / complications
Neoplasm Recurrence, Local / therapy
Obesity / complications*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Biological Products
axicabtagene ciloleucel